{"title":"Study on the Expression and Mechanism of Tumour-Derived IgG in Prostate Cancer","authors":"Hongmei Xia, Xiaojing Luo, Feng Zhang, W. Yin","doi":"10.29337/ijsonco.129","DOIUrl":"https://doi.org/10.29337/ijsonco.129","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84338692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Preclinical Researches of Vitamin D Role in Preventing Malignant Diseased, a Systematic Review","authors":"A. Udristioiu, Iulia Farmazon, M. Cojocaru","doi":"10.29337/ijsonco.130","DOIUrl":"https://doi.org/10.29337/ijsonco.130","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89165711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-01Epub Date: 2021-01-20DOI: 10.1097/ij9.0000000000000095
Amir Siddiqui, Navin Pinto, Mark A Applebaum, Grace Z Mak, John M Cunningham, James L LaBelle, Michele L Nassin
Desmoplastic small round cell tumor (DSRCT) is a rare, highly aggressive malignancy primarily affecting children and young adults. Although modest improvements have been gained by intensification of chemotherapy and radiation, survival of patients with DSRCT remains poor, particularly in those with unresectable or disseminated disease. We report 3 pediatric patients who were treated with a combination of therapy including chemotherapy, surgical debulking, hyperthermic intraperitoneal chemotherapy, whole abdominal irradiation, and autologous hematopoietic stem cell transplantation following busulfan and melphalan conditioning. We find that this approach is well tolerated and may offer improved survival in patients with DSRCT.
{"title":"The addition of autologous stem cell transplantation to neoadjuvant chemotherapy, radiation, and HIPEC for patients with unresectable desmoplastic small round cell tumor: a single center case series.","authors":"Amir Siddiqui, Navin Pinto, Mark A Applebaum, Grace Z Mak, John M Cunningham, James L LaBelle, Michele L Nassin","doi":"10.1097/ij9.0000000000000095","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000095","url":null,"abstract":"<p><p>Desmoplastic small round cell tumor (DSRCT) is a rare, highly aggressive malignancy primarily affecting children and young adults. Although modest improvements have been gained by intensification of chemotherapy and radiation, survival of patients with DSRCT remains poor, particularly in those with unresectable or disseminated disease. We report 3 pediatric patients who were treated with a combination of therapy including chemotherapy, surgical debulking, hyperthermic intraperitoneal chemotherapy, whole abdominal irradiation, and autologous hematopoietic stem cell transplantation following busulfan and melphalan conditioning. We find that this approach is well tolerated and may offer improved survival in patients with DSRCT.</p>","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40315073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1097/IJ9.0000000000000093
Xinran O Zhao, Ye Qin, Di Zhang, Yang Han, Guang-Ping Wu, Huanyu Zhao
Introduction: Lung cancer is the leading cause of cancer death worldwide. Histologic transformation from lung squamous cell carcinoma to small cell lung cancer (SCLC) has become more and more, and its treatment is challenging because of unknown pathogenesis. Presentation of Case: A 62-year-old male patient presented with histologic transformation from primary lesion to metastatic recurrence lesion within 3 years following primary lobectomy and adjuvant chemotherapy. The patient had the symptom of cough at the time of initial illness and recurrence. The primary lesion at the root segment of left superior lobe was diagnosed as lung squamous cell carcinoma without gene mutation (including EGFR, ALK, BRAF V600E, etc.), and recurrence lesion at the swollen lymph nodes in mediastinum (4L group) was diagnosed as SCLC. Up to now, the patient was alive for nearly 4 years after first surgery. Discussion: Surgical resection is the main treatment for lung cancer patient in early stage. Lymph node metastasis is a big threat for the patients in early stage. Recently, the research reports focused on the mechanism and cases of histologic transformation of lung cancer have become more and more. In this case, histologic transformation from squamous cell carcinoma in primary focus to SCLC in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy. However, there was no gene mutation. This is a very unusual report. Conclusion: We analyzed a lung cancer patient with histologic transformation from primary focus to lymphatic metastasis by clinical symptoms, radiologic features, laboratory tests, gene detection, histopathologic characteristics, and immunohistochemical testing. It is helpful to understand the pathogenesis of histologic transformation and metastatic progression for optimizing treatment measures to lung cancer.
{"title":"Histologic transformation from lung squamous cell carcinoma in primary lesion to small cell lung cancer in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy: a case report","authors":"Xinran O Zhao, Ye Qin, Di Zhang, Yang Han, Guang-Ping Wu, Huanyu Zhao","doi":"10.1097/IJ9.0000000000000093","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000093","url":null,"abstract":"Introduction: Lung cancer is the leading cause of cancer death worldwide. Histologic transformation from lung squamous cell carcinoma to small cell lung cancer (SCLC) has become more and more, and its treatment is challenging because of unknown pathogenesis. Presentation of Case: A 62-year-old male patient presented with histologic transformation from primary lesion to metastatic recurrence lesion within 3 years following primary lobectomy and adjuvant chemotherapy. The patient had the symptom of cough at the time of initial illness and recurrence. The primary lesion at the root segment of left superior lobe was diagnosed as lung squamous cell carcinoma without gene mutation (including EGFR, ALK, BRAF V600E, etc.), and recurrence lesion at the swollen lymph nodes in mediastinum (4L group) was diagnosed as SCLC. Up to now, the patient was alive for nearly 4 years after first surgery. Discussion: Surgical resection is the main treatment for lung cancer patient in early stage. Lymph node metastasis is a big threat for the patients in early stage. Recently, the research reports focused on the mechanism and cases of histologic transformation of lung cancer have become more and more. In this case, histologic transformation from squamous cell carcinoma in primary focus to SCLC in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy. However, there was no gene mutation. This is a very unusual report. Conclusion: We analyzed a lung cancer patient with histologic transformation from primary focus to lymphatic metastasis by clinical symptoms, radiologic features, laboratory tests, gene detection, histopathologic characteristics, and immunohistochemical testing. It is helpful to understand the pathogenesis of histologic transformation and metastatic progression for optimizing treatment measures to lung cancer.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80542848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1097/IJ9.0000000000000097
C. Cui, Xieqiao Yan, Ben Li, L. Si, C. Zhihong, X. Sheng, B. Lian, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Jun Guo
Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China. Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival. Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG ≥2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes. Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.
{"title":"Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China","authors":"C. Cui, Xieqiao Yan, Ben Li, L. Si, C. Zhihong, X. Sheng, B. Lian, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Jun Guo","doi":"10.1097/IJ9.0000000000000097","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000097","url":null,"abstract":"Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China. Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival. Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG ≥2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes. Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84300174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1097/IJ9.0000000000000094
D. Frisone, N. Gobin, P. Renard, S. Malekzadeh, C. Constantin, L. Barberini
Introduction: Gastrocolic fistula (GCF) is a rarely reported complication of numerous diseases. When associated with malignancies, the prognosis is usually poor. The classic presentation includes diarrhea, feculent vomiting, and weight loss. Presentation of Case: We hereby report the case of a patient who presented with weight loss and dyspepsia for 2 months, in the absence of diarrhea. Diagnosis of a GCF was made by performing a gastroscopy and a computed tomography scan. The biopsy taken during gastroscopy showed a lower tract gastrointestinal cancer, and the patient underwent surgical treatment by “en bloc” resection. After an anastomosis leak, he recovered well and underwent adjuvant chemotherapy. After a 3-year follow-up, the patient is alive and disease free. Discussion: This case presentation, together with a literature review, underlines that variable symptoms and signs that can be associated to this rare condition. The role of new imaging techniques such as computed tomography scan, compared with barium enema, should also be evaluated in this setting. The absence of lymph-node involvement may predict a good prognosis. Conclusion: GCF is a rare presentation of malignant diseases. In order to diagnose this rare condition a high grade of suspicion is needed, as symptoms are variable and most diagnostic tools are not sensitive enough to recognize it.
{"title":"Gastrocolic fistula: a case report","authors":"D. Frisone, N. Gobin, P. Renard, S. Malekzadeh, C. Constantin, L. Barberini","doi":"10.1097/IJ9.0000000000000094","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000094","url":null,"abstract":"Introduction: Gastrocolic fistula (GCF) is a rarely reported complication of numerous diseases. When associated with malignancies, the prognosis is usually poor. The classic presentation includes diarrhea, feculent vomiting, and weight loss. Presentation of Case: We hereby report the case of a patient who presented with weight loss and dyspepsia for 2 months, in the absence of diarrhea. Diagnosis of a GCF was made by performing a gastroscopy and a computed tomography scan. The biopsy taken during gastroscopy showed a lower tract gastrointestinal cancer, and the patient underwent surgical treatment by “en bloc” resection. After an anastomosis leak, he recovered well and underwent adjuvant chemotherapy. After a 3-year follow-up, the patient is alive and disease free. Discussion: This case presentation, together with a literature review, underlines that variable symptoms and signs that can be associated to this rare condition. The role of new imaging techniques such as computed tomography scan, compared with barium enema, should also be evaluated in this setting. The absence of lymph-node involvement may predict a good prognosis. Conclusion: GCF is a rare presentation of malignant diseases. In order to diagnose this rare condition a high grade of suspicion is needed, as symptoms are variable and most diagnostic tools are not sensitive enough to recognize it.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75718206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1097/IJ9.0000000000000104
H. Iwasaki, S. Toda, Daisuke Murayama, A. Matsui
Introduction: Pulmonary metastasis originating from differentiated thyroid cancer is rare. Pulmonary metastasis generally progresses slowly and results in a relatively long prognosis when treated with radioactive iodine therapy and thyroid-stimulating hormone suppression therapy. However, some cases still result in death. Since 2015, lenvatinib administration for pulmonary metastases with disease progression has yielded satisfactory results. Materials and methods: Among the 798 patients with differentiated thyroid cancer treated at Kanagawa Cancer Center, Japan, between April 2015 and March 2020, 194 had distant metastasis. Of these 194 patients, 118 diagnosed with pulmonary metastasis had lesions that influence the prognosis. We retrospectively investigated the transition of the maximum diameter of pulmonary metastases, serum thyroglobulin, follow-up, and survival time. Results: We included 83 follow-up cases and 35 patients treated with lenvatinib. Considering that the disease progressed, 35 patients were treated with lenvatinib, and 4 died from cancer-specific disease. Treatment results were evaluated as progressive disease, stable disease, and partial response in 2, 11, and 22 patients, respectively. Conclusions: Among pulmonary metastases, no death occurred because of relatively slow disease progression up to a maximum diameter of 10 mm. However, when the size exceeded 15 mm, radioactive iodine treatment and thyroid-stimulating hormone suppression therapy did not work, and disease progression accelerated. As long as the lenvatinib treatment could be continued, the disease could be controlled satisfactorily. The patients who discontinued lenvatinib died from disease progression.
{"title":"Analysis of disease progression and prognosis in differentiated thyroid cancer with pulmonary metastases: a retrospective study","authors":"H. Iwasaki, S. Toda, Daisuke Murayama, A. Matsui","doi":"10.1097/IJ9.0000000000000104","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000104","url":null,"abstract":"Introduction: Pulmonary metastasis originating from differentiated thyroid cancer is rare. Pulmonary metastasis generally progresses slowly and results in a relatively long prognosis when treated with radioactive iodine therapy and thyroid-stimulating hormone suppression therapy. However, some cases still result in death. Since 2015, lenvatinib administration for pulmonary metastases with disease progression has yielded satisfactory results. Materials and methods: Among the 798 patients with differentiated thyroid cancer treated at Kanagawa Cancer Center, Japan, between April 2015 and March 2020, 194 had distant metastasis. Of these 194 patients, 118 diagnosed with pulmonary metastasis had lesions that influence the prognosis. We retrospectively investigated the transition of the maximum diameter of pulmonary metastases, serum thyroglobulin, follow-up, and survival time. Results: We included 83 follow-up cases and 35 patients treated with lenvatinib. Considering that the disease progressed, 35 patients were treated with lenvatinib, and 4 died from cancer-specific disease. Treatment results were evaluated as progressive disease, stable disease, and partial response in 2, 11, and 22 patients, respectively. Conclusions: Among pulmonary metastases, no death occurred because of relatively slow disease progression up to a maximum diameter of 10 mm. However, when the size exceeded 15 mm, radioactive iodine treatment and thyroid-stimulating hormone suppression therapy did not work, and disease progression accelerated. As long as the lenvatinib treatment could be continued, the disease could be controlled satisfactorily. The patients who discontinued lenvatinib died from disease progression.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84328310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01DOI: 10.1097/IJ9.0000000000000090
M. Baig, J. Weber, C. Connery, F. Bhora
Introduction: Primary tracheal cancers have a yearly prevalence of 2.6 cases per million people. Because of their rarity there is a lack of studies investigating them. In this study, we investigate the clinical characteristics and outcomes of primary tracheal cancers using a large population database. Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried between 1973 and 2016 to identify a retrospective cohort of patients with primary tracheal cancers. Demographic information, tumor characteristics, treatments administered, and survival in months were investigated. Results: Eight hundred sixty-eight cases were analyzed. The majority of the patients were male (56.8%) with an average age of 62.13 (±15.67). Squamous cell carcinoma (SCC) was the predominant subtype (42.9%) followed by adenoid cystic carcinoma (ACC) (18.1%). Five-year survival was 21.6% and median survival was 12 months. Patients with ACC had more localized tumors, received surgery more often and had longer survival than patients with SCC (P<0.01). Both groups had best outcomes when treated with surgery. Bronchoscopic intervention was associated with favorable outcomes for ACC. For SCCs, bronchoscopic interventions followed by adjuvant therapy had better outcomes than radiotherapy alone. Cox proportional hazards identified advanced age and stage, radiotherapy and chemotherapy as negative predictors of outcome. Whereas ACC and sarcoma histology and diagnosis between 2010 and 2016 were positive prognosticators. Conclusions: Tracheal cancers have poor outcomes with a median survival of 12 months and 5-year survival of only 21.6%. Surgical resection should be the treatment of choice wherever feasible. In patients with ACCs who are not surgical candidates bronchoscopic interventions may provide appropriate treatment and palliation and improved survival. For SCCs, bronchoscopic intervention wherever possible with adjuvant therapy may be favorable to radiotherapy alone.
{"title":"A SEER database cohort of 868 patients with primary tracheal cancers: characteristics and outcomes and the role of bronchoscopic interventions","authors":"M. Baig, J. Weber, C. Connery, F. Bhora","doi":"10.1097/IJ9.0000000000000090","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000090","url":null,"abstract":"Introduction: Primary tracheal cancers have a yearly prevalence of 2.6 cases per million people. Because of their rarity there is a lack of studies investigating them. In this study, we investigate the clinical characteristics and outcomes of primary tracheal cancers using a large population database. Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried between 1973 and 2016 to identify a retrospective cohort of patients with primary tracheal cancers. Demographic information, tumor characteristics, treatments administered, and survival in months were investigated. Results: Eight hundred sixty-eight cases were analyzed. The majority of the patients were male (56.8%) with an average age of 62.13 (±15.67). Squamous cell carcinoma (SCC) was the predominant subtype (42.9%) followed by adenoid cystic carcinoma (ACC) (18.1%). Five-year survival was 21.6% and median survival was 12 months. Patients with ACC had more localized tumors, received surgery more often and had longer survival than patients with SCC (P<0.01). Both groups had best outcomes when treated with surgery. Bronchoscopic intervention was associated with favorable outcomes for ACC. For SCCs, bronchoscopic interventions followed by adjuvant therapy had better outcomes than radiotherapy alone. Cox proportional hazards identified advanced age and stage, radiotherapy and chemotherapy as negative predictors of outcome. Whereas ACC and sarcoma histology and diagnosis between 2010 and 2016 were positive prognosticators. Conclusions: Tracheal cancers have poor outcomes with a median survival of 12 months and 5-year survival of only 21.6%. Surgical resection should be the treatment of choice wherever feasible. In patients with ACCs who are not surgical candidates bronchoscopic interventions may provide appropriate treatment and palliation and improved survival. For SCCs, bronchoscopic intervention wherever possible with adjuvant therapy may be favorable to radiotherapy alone.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87842137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-26DOI: 10.1097/IJ9.0000000000000091
L. Cranmer, Bonny Chau, Matthew J. Thompson, E. Loggers, S. Pollack, M. Wagner, Teresa S. Kim, Edward Y. Kim, G. Kane, G. Pavey
Supplemental Digital Content is available in the text. Objectives: Factors associated with nodal involvement in chondrosarcoma and outcomes based on treatment modality were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Chondrosarcomas involving axial and appendicular parts of the body diagnosed from 2004 to 2015 were identified in SEER. Clinical, pathologic, and treatment parameters were compared with respect to nodal status at initial diagnosis by Fisher’s exact or Student’s t-test. Disease-specific survival (DSS) and overall survival (OS) were evaluated by Kaplan-Meier analyses, and by Cox regression models. Results: Synchronous regional nodal metastases were present in 1.3% of chondrosarcoma patients. Lymph node involvement was associated with primary tumor location in extraskeletal tissue and the pelvis, and with distant metastasis and larger primary tumor size at diagnosis. Patients with nodal involvement had 5-year DSS of 48% [95% confidence interval (CI): 28%–65%], versus 82% (95% CI: 80%–84%) for those without (log-rank P<0.001). 5-year OS with and without nodal involvement were 38% (95% CI: 21%–55%) and 73% (95% CI: 71%–75%), respectively (log-rank P<0.001). Surgical excision of nodes was associated with improved DSS and OS. Radiation and chemotherapy were not associated with improved DSS/OS. Conclusions: The nodal disease is uncommon at presentation in chondrosarcoma. Greater clinical vigilance for regional nodal metastases may be warranted for those with specific risk factors, including extraskeletal or pelvic primary sites, myxoid, mesenchymal, or dedifferentiated histologies, and large size. Surgical excision of regional nodes is associated with improved DSS/OS. This analysis suggests a therapeutic effect of surgical treatment, rather than selection for favorable underlying biological factors.
{"title":"Impact of nodal involvement on survival outcomes in chondrosarcoma: retrospective cohort analysis of Surveillance, Epidemiology, and End Results (SEER) database (2004–2015)","authors":"L. Cranmer, Bonny Chau, Matthew J. Thompson, E. Loggers, S. Pollack, M. Wagner, Teresa S. Kim, Edward Y. Kim, G. Kane, G. Pavey","doi":"10.1097/IJ9.0000000000000091","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000091","url":null,"abstract":"Supplemental Digital Content is available in the text. Objectives: Factors associated with nodal involvement in chondrosarcoma and outcomes based on treatment modality were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Chondrosarcomas involving axial and appendicular parts of the body diagnosed from 2004 to 2015 were identified in SEER. Clinical, pathologic, and treatment parameters were compared with respect to nodal status at initial diagnosis by Fisher’s exact or Student’s t-test. Disease-specific survival (DSS) and overall survival (OS) were evaluated by Kaplan-Meier analyses, and by Cox regression models. Results: Synchronous regional nodal metastases were present in 1.3% of chondrosarcoma patients. Lymph node involvement was associated with primary tumor location in extraskeletal tissue and the pelvis, and with distant metastasis and larger primary tumor size at diagnosis. Patients with nodal involvement had 5-year DSS of 48% [95% confidence interval (CI): 28%–65%], versus 82% (95% CI: 80%–84%) for those without (log-rank P<0.001). 5-year OS with and without nodal involvement were 38% (95% CI: 21%–55%) and 73% (95% CI: 71%–75%), respectively (log-rank P<0.001). Surgical excision of nodes was associated with improved DSS and OS. Radiation and chemotherapy were not associated with improved DSS/OS. Conclusions: The nodal disease is uncommon at presentation in chondrosarcoma. Greater clinical vigilance for regional nodal metastases may be warranted for those with specific risk factors, including extraskeletal or pelvic primary sites, myxoid, mesenchymal, or dedifferentiated histologies, and large size. Surgical excision of regional nodes is associated with improved DSS/OS. This analysis suggests a therapeutic effect of surgical treatment, rather than selection for favorable underlying biological factors.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91371628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-26DOI: 10.1097/IJ9.0000000000000089
K. Nio, K. Tsuchihashi, K. Taguchi, Tomoyasu Yoshihiro, K. Yamaguchi, Mamoru Ito, Shohei Moriyama, Mitsuhiro Fukata, T. Fujiwara, Nokitaka Setsu, M. Endo, Y. Matsumoto, Y. Nakashima, T. Wakasaki, R. Yasumatsu, H. Ariyama, H. Kusaba, J. Kishimoto, K. Akashi, E. Baba
Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical practice. We retrospectively analyzed data derived from 29 patients with thyroid cancer or soft tissue sarcoma (STS) treated with lenvatinib (n=10) and pazopanib (n=19). Eight (arterial n=4; venous n=4) thromboembolic events developed in 6 (20%) patients. Thromboembolisms occurred during a mean of 149 (range, 42–847) days from starting TKI. The primary disease progressed in all patients with thromboembolism. The overall survival durations of patients with and without improved thromboembolism were 572 [95% confidence interval (CI), 225– 918] and 176 (95% CI, 84–394) days, respectively, which did not significantly differ (P=0.33). Patients with and without improved thromboembolism survived after onset for 122 (95% CI, 71–173) versus 27 (95% CI, 21–42) days (P=0.049), which significantly differed. Univariate analysis and variate selection for multivariate analysis selected a history of thromboembolism as the most powerful risk factor for new thromboembolism. In summary, the frequency of thromboembolism in clinical practice was higher than that in previous clinical trials. Furthermore, a history of thromboembolism was a risk factor for the development of new thromboembolism in patients treated with TKI. Thromboembolism developed particularly as the primary disease progressed. Our findings require validation in a large-scale study.
{"title":"Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib","authors":"K. Nio, K. Tsuchihashi, K. Taguchi, Tomoyasu Yoshihiro, K. Yamaguchi, Mamoru Ito, Shohei Moriyama, Mitsuhiro Fukata, T. Fujiwara, Nokitaka Setsu, M. Endo, Y. Matsumoto, Y. Nakashima, T. Wakasaki, R. Yasumatsu, H. Ariyama, H. Kusaba, J. Kishimoto, K. Akashi, E. Baba","doi":"10.1097/IJ9.0000000000000089","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000089","url":null,"abstract":"Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical practice. We retrospectively analyzed data derived from 29 patients with thyroid cancer or soft tissue sarcoma (STS) treated with lenvatinib (n=10) and pazopanib (n=19). Eight (arterial n=4; venous n=4) thromboembolic events developed in 6 (20%) patients. Thromboembolisms occurred during a mean of 149 (range, 42–847) days from starting TKI. The primary disease progressed in all patients with thromboembolism. The overall survival durations of patients with and without improved thromboembolism were 572 [95% confidence interval (CI), 225– 918] and 176 (95% CI, 84–394) days, respectively, which did not significantly differ (P=0.33). Patients with and without improved thromboembolism survived after onset for 122 (95% CI, 71–173) versus 27 (95% CI, 21–42) days (P=0.049), which significantly differed. Univariate analysis and variate selection for multivariate analysis selected a history of thromboembolism as the most powerful risk factor for new thromboembolism. In summary, the frequency of thromboembolism in clinical practice was higher than that in previous clinical trials. Furthermore, a history of thromboembolism was a risk factor for the development of new thromboembolism in patients treated with TKI. Thromboembolism developed particularly as the primary disease progressed. Our findings require validation in a large-scale study.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78161119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号